[Asia Economy Reporter Oh Ju-yeon] FutureChem announced on the 9th that it has obtained a U.S. patent for an 18F-labeled compound for prostate cancer diagnosis and its use.
The company explained, "This invention relates to a PET radiopharmaceutical for diagnosing prostate cancer. The compound of this invention is characterized by selectively binding to Prostate-Specific Membrane Antigen (PSMA), which is overexpressed in prostate cancer cells."
It added, "The FC303 (compound name: Florastamin) of this invention has a strong binding affinity to the PSMA protein and is a hydrophilic substance that dissolves well in water. It has the advantage of minimal uptake in normal organs and rapid elimination of excess drug through the kidneys, enabling clearer prostate cancer imaging in a short time."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
